Loading organizations...
§ Private Profile · Redwood City, CA, USA
Petal Surgical is a technology company.
Petal is redefining surgery with an intricate interplay of precisely directed sound waves with diseased cells. Our platform uses Acoustic Liquefaction - focused acoustic energy to break down targeted tissue without incisions, heat, or trauma enabling the body to heal itself naturally.
Petal Surgical has raised $10.0M across 1 funding round.
Petal Surgical has raised $10.0M in total across 1 funding round.
Petal Surgical has raised $10.0M across 1 funding round. Most recently, it raised $10.0M Series A in October 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Oct 1, 2025 | $10M Series A | K50 Ventures, TSVC | Sonder Capital, Tsvc Capital, Eliot Horowitz, Fred Moll, M.D, Draper, ShangBay Capital | Announced |
Petal Surgical has raised $10.0M in total across 1 funding round.
Petal Surgical's investors include K50 Ventures, TSVC, Sonder Capital, TSVC Capital, Eliot Horowitz, Fred Moll, M.D, Draper, ShangBay Capital.
Petal Surgical is a cutting-edge surgical technology company pioneering incisionless surgery through a proprietary method called Acoustic Sculpting, a refined form of histotripsy that uses focused acoustic energy to break down targeted tissue without incisions, heat, or trauma. Their platform integrates ultrasound-based acoustic liquefaction with robotics, AI, and image guidance to enable outpatient, scalable surgical treatments primarily targeting cancer initially, with potential applications in cardiovascular and musculoskeletal conditions. Petal serves surgeons and patients by offering a less invasive, safer alternative to traditional surgery that reduces complications, recovery time, and healthcare costs[1][3][4].
Founded in 2021 and based in San Francisco, Petal Surgical was co-founded by Prash Chopra, a veteran of surgical robotics companies Intuitive Surgical and Verb Surgical, alongside a leadership team with deep expertise in neurosurgery, medical robotics, and advanced energy systems. The idea emerged from a desire to fundamentally transform surgery by eliminating incisions, excisions, and suturing, focusing on ultrasound histotripsy rather than radiation. After several years of research and refinement, the company developed an end-to-end solution that integrates acoustic liquefaction with AI and robotics to create a new standard of care that is incisionless and outpatient-ready[1][2][3][4].
Petal Surgical rides the wave of minimally invasive and noninvasive surgical innovation, leveraging advances in ultrasound energy, robotics, and AI to disrupt traditional surgical paradigms. The timing is critical as healthcare systems seek to reduce costs, complications, and hospital stays while improving patient outcomes. Market forces such as the growing demand for outpatient procedures, rising prevalence of cancer and chronic diseases, and technological maturation of histotripsy and robotic systems favor Petal’s approach. By potentially replacing incisions with sound waves, Petal is poised to influence the broader ecosystem by setting new standards for surgical care and enabling new treatment modalities beyond ablation, including cardiovascular and pain management applications[1][4].
Petal Surgical’s next phase involves expanding clinical evidence and regulatory approvals to validate and broaden its applications beyond cancer ablation to cardiovascular, stroke, pain, and connective tissue disorders. The company’s vision of making incisionless surgery the standard of care aligns with broader trends toward patient-centric, outpatient, and technology-enabled healthcare. As the platform matures, Petal could significantly reduce surgical risks and costs while improving access to curative therapies, reshaping how surgery is performed globally. Their influence is likely to grow as they demonstrate scalability and socioeconomic impact, potentially transforming surgery from an invasive procedure to a precise, sound-based intervention[4][5][6].